Cancer Research2d
American Association for Cancer Research
Clin Cancer Res (2025) 31 (2_Supplement): B028.
Cancer Research2d
Abstract IA01: Moving forward translation of targeted therapy with external beam radiation
1Geman Cancer Research Center DKFZ, Heidelberg, Germany.
Cancer Research2d
American Association for Cancer Research
Clin Cancer Res (2025) 31 (2_Supplement): P008.
Cancer Research2d
Abstract IA03: Tumor draining lymph nodes: Friends or foes
1Stanford University, Stanford, CA.
Cancer Research2d
Abstract B015: PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity
Search for other works by this author on: ...
Cancer Research2d
Abstract B033: Long-Term quality of life and hearing preservation after stereotactic radiosurgery for vestibular schwannoma
Search for other works by this author on: ...
Cancer Research2d
Abstract B014: Dual checkpoint blockade mitigates the immunosuppressive effects of radiotherapy amplified by experimental liver metastasis
1UCSF, San Francisco, CA.
Cancer Research2d
Abstract B008: Understanding myeloid and lymphoid cell heterogeneity following radiotherapy and its impact on metastasis development in breast cancer
Breast cancer (BC) is the most frequent malignancy in women worldwide and the gold standard for its treatment currently entails resection of the primary tumor, followed by radiotherapy (RT), ...
Cancer Research2d
Abstract B012: Interferon- γ is required for immunotherapy induced radiosensitivity in solid tumors
Radiation therapy (RT) is the standard of care for many cancer types, however, some solid tumors fail to respond due to factors such as a hypoxic tumor microenvironment (TME). To overcome ...
Cancer Research2d
Abstract A011: Activity of antibody-drug conjugates with radiation in preclinical bladder cancer models
Antibody-drug conjugates (ADCs) are transforming the treatment landscape in metastatic bladder cancer, but the role of ADCs in localized disease is uncertain. Radiation is a central component of ...
Cancer Research6d
Challenges to Innovation Arising from Current Companion Diagnostic Regulations and Suggestions for Improvements
1Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.